Phase 3 studies point to sustained disease control in patients who remain symptomatic despite standard therapies.

If the FeNO level is not raised, it is recommended that the patient be offered either a Long-Acting Muscarinic Antagonist ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...

Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial KT-621 BROADEN2 Phase ...

Personal narratives on allergy and asthma conditions which contained inaccuracies gained the most traction online.

Objective Systemic corticosteroids for 5–7 days are standard care for asthma exacerbations, but the optimal duration and ...

FeNO testing is increasingly recognized as a key first step in asthma assessment under the updated UK guidelines.

Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a ...

A monthly injection has helped 90% of severe asthma patients reduce daily steroid tablets, which are associated with long-term side effects. More than half of the participants who had received the ...

Enveda, a clinical-stage biotech company pioneering the discovery and development of a new generation of small-molecule drugs derived from life's chemistry, today announced that it has initiated two ...

Monthly injection with tezepelumab helped 90% of patients with severe asthma reduce intake of daily steroid tablets. The ...

Learn how eczema presents differently on skin of color and the impact on mental health. Find resources for identification, ...